Physician profile
David E Szymanski
NPI 1912904921
$1,656.22
in general payments reported to CMS, 2019-2025
13 companies · $440 in 2025
The $440 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2022: $72.99 · 2023: $111 · 2024: $74.74 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $945.39 | 2019 | |
| Abbvie INC. | $234.14 | 2025 | |
| Acadia Pharmaceuticals INC | $140.88 | 2022-2025 | Nuplazid |
| Ucb, INC. | $85.58 | 2024-2025 | Briviact, Nayzilam |
| Pfizer INC. | $76.98 | 2023-2025 | |
| Eisai INC. | $35.33 | 2023-2024 | |
| Emd Serono, INC. | $28.13 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.74 | 2022 | |
| Amneal Pharmaceuticals LLC | $21.18 | 2025 | Crexont |
| Neurelis, INC. | $19.17 | 2023 | Valtoco |
| Sk Life Science, INC. | $14.97 | 2024 | |
| Argenx US, INC. | $14.66 | 2025 | Vyvgart Hytrulo |
| Impel Pharmaceuticals INC. | $14.07 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Szymanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.